Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 5C22H24N2O8.Na.O3P.5HO3P |
Molecular Weight | 2724.034 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 25 / 25 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O.CN(C)[C@H]5[C@@H]6C[C@H]7C(C(=O)C8=C(C=CC=C8O)[C@@]7(C)O)=C(O)[C@]6(O)C(=O)C(C(N)=O)=C5O.CN(C)[C@H]9[C@@H]%10C[C@H]%11C(C(=O)C%12=C(C=CC=C%12O)[C@@]%11(C)O)=C(O)[C@]%10(O)C(=O)C(C(N)=O)=C9O.CN(C)[C@H]%13[C@@H]%14C[C@H]%15C(C(=O)C%16=C(C=CC=C%16O)[C@@]%15(C)O)=C(O)[C@]%14(O)C(=O)C(C(N)=O)=C%13O.CN(C)[C@H]%17[C@@H]%18C[C@H]%19C(C(=O)C%20=C(C=CC=C%20O)[C@@]%19(C)O)=C(O)[C@]%18(O)C(=O)C(C(N)=O)=C%17O
InChI
InChIKey=DKNFPOTZPZOJHC-LBTQIPEASA-M
InChI=1S/5C22H24N2O8.Na.6HO3P/c5*1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28;;6*1-4(2)3/h5*4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30);;6*(H,1,2,3)/q;;;;;+1;;;;;;/p-1/t5*9-,10-,15-,21+,22-;;;;;;;/m00000......./s1
Molecular Formula | C22H24N2O8 |
Molecular Weight | 444.4346 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | HO3P |
Molecular Weight | 79.9799 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Discovered as natural products from actinomycetes soil bacteria, the tetracyclines were first reported in the scientific literature in 1948. They were noted for their broad spectrum antibacterial activity and were commercialized with clinical success beginning in the late 1940s to the early 1950s. By catalytic hydrogenation of Aureomycin, using palladium metal and hydrogen, the C7 deschloro derivative was synthesized, producing a compound of higher potency, a better solubility profile, and favorable pharmacological activity; it was subsequently named tetracycline. Tetracyclines are primarily bacteriostatic and exert their antimicrobial effect by the inhibition of protein synthesis by binding to the 30S ribosomal subunit. Tetracycline is active against a broad range of gram-negative and gram-positive organisms. Tetracycline is indicated in the treatment of infections caused by susceptible strains. To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline
hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or
prevent infections that are proven or strongly suspected to be caused by bacteria.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01114a057 | http://pubs.acs.org/doi/abs/10.1021/ja01114a537
Curator's Comment: References retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13117662 # Pfizer and Lederle Laboratories
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TETRACYCLINE HYDROCHLORIDE Approved UseTetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:
• Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae. Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible.
• Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae,
Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.)
• Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus.
(Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.)
• Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections,
Q fever, rickettsialpox.
• Psittacosis caused by Chlamydophila psittaci.
• Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal
infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum.
• Granuloma inquinale caused by Klebsiella granulomatis.
• Relapsing fever caused by Borrelia sp.
• Bartonellosis caused by Bartonella bacilliformis.
• Chancroid caused by Hemophilus ducreyi.
• Tularemia caused by Francisella tularensis.
• Plaque caused by Yersinia pestis.
• Cholera caused by Vibrio cholerae.
• Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside).
• Infections due to Campylobacter fetus.
• As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica.
• Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc.
• Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp.
• In severe acne, adjunctive therapy with tetracycline may be useful.
When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections:
• Syphilis and yaws caused by Treponema pallidum and pertenue, respectively,
• Vincent’s infection caused by Fusobacterium fusiforme,
• Infections caused by Neisseria gonorrhoeae,
• Anthrax caused by Bacillus anthracis,
• Infections due to Listeria monocytogenes,
• Actinomycosis caused by Actinomyces species,
• Infections due to Clostridium species. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
4.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.91 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
27.27 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg 2 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
27 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
31.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
25.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
74.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
55.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
56.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6487493/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
7.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
8.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/856000/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg 1 times / day multiple, oral Recommended Dose: 1000 mg, 1 times / day Route: oral Route: multiple Dose: 1000 mg, 1 times / day Sources: |
unhealthy, 14 - 35 years Health Status: unhealthy Age Group: 14 - 35 years Sex: M+F Sources: |
|
2.2 |500 mg/mL|mg 2 times / day multiple, topical|oral Dose: 2.2 |500 mg/mL|mg, 2 times / day Route: topical|oral Route: multiple Dose: 2.2 |500 mg/mL|mg, 2 times / day Sources: |
unhealthy, 14 - 35 years Health Status: unhealthy Age Group: 14 - 35 years Sex: M+F Sources: |
Other AEs: Discoloration skin... |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 38 years |
Disc. AE: Mucosal ulceration... AEs leading to discontinuation/dose reduction: Mucosal ulceration (1 patient) Sources: |
7 g multiple, intrapleural Overdose Dose: 7 g Route: intrapleural Route: multiple Dose: 7 g Sources: |
unhealthy, 41 years |
Disc. AE: Pleural disorder... AEs leading to discontinuation/dose reduction: Pleural disorder Sources: |
2 % 2 times / day multiple, intralesional Dose: 2 %, 2 times / day Route: intralesional Route: multiple Dose: 2 %, 2 times / day Sources: |
unhealthy, 63 years (range: 53–72 years) Health Status: unhealthy Age Group: 63 years (range: 53–72 years) Sex: M+F Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Discoloration skin | 2.2 |500 mg/mL|mg 2 times / day multiple, topical|oral Dose: 2.2 |500 mg/mL|mg, 2 times / day Route: topical|oral Route: multiple Dose: 2.2 |500 mg/mL|mg, 2 times / day Sources: |
unhealthy, 14 - 35 years Health Status: unhealthy Age Group: 14 - 35 years Sex: M+F Sources: |
|
Mucosal ulceration | 1 patient Disc. AE |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: |
unhealthy, 38 years |
Pleural disorder | Disc. AE | 7 g multiple, intrapleural Overdose Dose: 7 g Route: intrapleural Route: multiple Dose: 7 g Sources: |
unhealthy, 41 years |
PubMed
Title | Date | PubMed |
---|---|---|
Megaloblastic anemia associated with long-term tetracycline therapy. Report of a case. | 1973 Jun |
|
Tetracycline-induced immune hemolytic anemia. | 1974 May-Jun |
|
Therapeutic efficacy of tobramycin--a clinical and laboratory evaluation. | 1975 Dec |
|
Benign intracranial hypertension following tetracycline therapy. | 1975 Jul |
|
Fatty liver induced by tetracycline in the rat. Dose-response relationships and effect of sex. | 1975 Sep |
|
Tetracycline-associated intracranial hypertension in an adolescent: a complication of systemic acne therapy. | 1978 Apr |
|
Acne. | 1979 Dec |
|
Tetracycline-induced aplastic anemia. | 1979 Mar |
|
Drug-induced myocarditis: a report of two cases. | 1979 May-Jun |
|
Effect of toxic doses of progesterone on hepatotoxic effects of tetracycline. | 1985 Apr |
|
Selective absorption of ultraviolet laser energy by human atherosclerotic plaque treated with tetracycline. | 1985 May 1 |
|
Minor complication of thyroid cyst sclerosis with tetracycline. | 1986 Jan |
|
Pseudotumor cerebri--a complication of tetracycline treatment of acne. | 1986 Mar |
|
An aborted, prospective, randomized trial of sclerotherapy for prolonged drainage after mastectomy. | 1986 May |
|
[Effectiveness of legalon and essentiale in a tetracycline-induced liver lesion]. | 1986 Oct |
|
Tetracycline-induced renal hypophosphatemia in a patient with a syndrome of inappropriate secretion of antidiuretic hormone. | 1988 |
|
Pseudotumor cerebri, a rare adverse reaction to tetracycline therapy. A case report. | 1988 Dec |
|
Anosmia after doxycycline use. | 1990 Apr 16 |
|
Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. | 1990 Jan-Feb |
|
In vitro and in vivo effects of doxycycline on Toxoplasma gondii. | 1990 May |
|
[Clinical use of tetracyclines in the treatment of periodontal diseases]. | 2000 May-Jun |
|
One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study. | 2001 Dec |
|
Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. | 2001 Feb |
|
Tetracycline-Cu(II) photo-induced fragmentation of serum albumin. | 2002 Apr |
|
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. | 2002 Feb |
|
Antimicrobial and anti-lipase activity of quercetin and its C2-C16 3-O-acyl-esters. | 2002 Feb |
|
Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. | 2002 Feb 10 |
|
Human organic anion transporters mediate the transport of tetracycline. | 2002 Jan |
|
Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. | 2002 Oct |
|
The outcome of pseudotumor cerebri induced by tetracycline therapy. | 2004 Dec |
|
Pyomyositis caused by methicillin-resistant Staphylococcus aureus. | 2005 Apr 7 |
|
[Intracranial hypertension with severe and irreversible reduced acuity and impaired visual fields after oral tetracycline]. | 2005 Aug 20 |
|
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). | 2005 May |
|
Fatal brain abscess due to community-associated methicillin-resistant Staphylococcus aureus strain USA300. | 2007 Nov 1 |
|
Acute hepatotoxicity: a predictive model based on focused illumina microarrays. | 2007 Sep |
|
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008 Aug |
|
Meningitis due to hematogenous dissemination of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in a patient with AIDS. | 2008 Nov-Dec |
|
Cellular imaging predictions of clinical drug-induced liver injury. | 2008 Sep |
|
Tetracycline-induced renal failure after dental treatment. | 2009 Jan |
|
Protective effect of bicyclol on tetracycline-induced fatty liver in mice. | 2009 Jul 10 |
|
Gel entrapment culture of rat hepatocytes for investigation of tetracycline-induced toxicity. | 2009 Jul 15 |
|
Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment. | 2010 Jan |
|
Epidural abscess caused by community-associated methicillin-resistant Staphylococcus aureus strain USA300 in Japan. | 2010 Oct |
|
Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. | 2010 Sep |
|
Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | 2011 Aug |
|
Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. | 2012 Jan 26 |
|
Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. | 2012 May |
|
Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. | 2013 Feb 15 |
|
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. | 2013 Jun |
|
A simple transcriptomic signature able to predict drug-induced hepatic steatosis. | 2014 Apr |
Patents
Sample Use Guides
TETRACYCLINE HYDROCHLORIDE - tetracycline hydrochloride capsule
Adults: Usual daily dose, 1 gram as 500 mg twice a day or 250 mg four times a day. Higher doses such as 500 mg four times a day may be required for severe infections or for those infections which do not respond to the smaller doses.
For pediatric patients above eight years of age: Usual daily dose, 10 mg/lb to 20 mg/lb (25mg/kg to 50 mg/kg) body weight divided in four equal doses.
TETRACYCLINE VISION 10 mg/g eye ointment
Adults and children: depending on the severity of condition, a strip of the eye ointment with length of 1 – 1.5 cm is inserted into the conjunctival fold of the lower eyelid 3 - 4 times daily and in more severe cases, up to 6 times daily.
Route of Administration:
Other
Standard tetracycline powders should provide the following range of Minimal Inhibitory Concentration values:
Enterococcus faecalis ATCC 29212 8 - 32 mcg/mL
Escherichia coli ATCC 25922 0.5 - 2 mcg/mL
Haemophilus influenzae ATCC 49247 4 - 32 mcg/mL
Mycoplasma pneumoniae ATCC 29342 0.06-0.5 mcg/mL
Staphylococcus aureus ATCC 29213 0.12 - 1 mcg/mL
Streptococcus pneumoniae ATCC 49619 0.06 - 0.5 mcg/mL
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:20 GMT 2025
by
admin
on
Mon Mar 31 17:35:20 GMT 2025
|
Record UNII |
6B7BK5H33B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.2345F
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
||
|
NCI_THESAURUS |
C1595
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C87225
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
2105975
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL1440
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
100000084818
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
73050795
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
15664-14-9
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
ALTERNATIVE | |||
|
1336-20-5
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
6B7BK5H33B
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
m10611
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB04761MIG
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY | |||
|
215-646-0
Created by
admin on Mon Mar 31 17:35:20 GMT 2025 , Edited by admin on Mon Mar 31 17:35:20 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |